top of page
it's where dermatology lives
John Evans
Feb 25, 20222 min read
MCC recurrence rate 40%
Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40%—markedly higher than the recurrence rates for...
John Evans
Sep 24, 20212 min read
Pembrolizumab lowered risk of stage IIb/c melanoma recurrence
The immunotherapy medication pembrolizumab, approved for the treatment of stage III and IV melanoma, has been shown to reduce...
Featured Posts
bottom of page